S

Stryker

Manufactures orthopedic and surgical medical devices

Territory Manager - Neurovascular

Full-Time
No salary listed
Mid
Bachelor's
Sydney NSW, Australia
In PersonNSW-based territory with regular travel to customer sites.
Sales & Account ManagementField Sales

About the job

Requirements
  • Demonstrated sales experience with strong commercial and account management capability.
  • Experience managing customer accounts and commercial opportunities.
  • Ability to work in customer-facing environments and independently manage territory priorities.
Responsibilities
  • Build and maintain long-term relationships with specialist clinicians and key hospital stakeholders.
  • Provide in-procedure clinical support and develop detailed knowledge of Neurovascular anatomy, imaging, procedures, and Stryker technology.
  • Manage an established territory, protect existing business, and identify opportunities for sustainable growth.
  • Introduce new products and support customers in adopting new Neurovascular technologies.
  • Develop strategic account and territory plans based on customer needs and commercial opportunities.
  • Manage product inventory, usage, replenishment, and customer ordering.
  • Prepare for upcoming procedures and coordinate customer and product requirements.
  • Collaborate with the wider Neurovascular team across Australia.
Desired Qualifications
  • Minimum 4 years of sales experience within medical devices or healthcare.
  • Experience in hospital, procedural, or other complex clinical environments.
  • Experience managing key or strategic customer accounts.
  • Tertiary qualification in medicine, healthcare, sales, marketing, or a related discipline.

About the company

S

Stryker

View
cbWebsite

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stryker Corporation
Oct 27th, 2026
Stryker Completes Acquisition of MAKO Surgical Corp.

Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics. "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals," said Kevin A. Lobo, President and Chief Executive Officer. As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in

Yahoo Finance
Oct 21st, 2026
P&G and Stryker: two dividend stocks to hold for decades

Procter & Gamble and Stryker are two dividend stocks suited to long-term holders, according to the article. Both sell products people need in any economy. P&G has raised its dividend for 70 consecutive years. In fiscal 2026, it posted net sales of about $87 billion, up 3%, and net earnings of $16.1 billion. It returned more than $15 billion to shareholders, including $10.2 billion in dividends. Organic sales and core earnings per share each grew just 1%. Stryker has raised its dividend for more than three decades. Second-quarter 2026 revenue rose 9.4% to $6.6 billion, and adjusted earnings per share climbed 17.9% to $3.69. Demand should gain from an ageing US population, though recalls, acquisition costs, and hospital spending pressures remain risks.

Yahoo Finance
Oct 14th, 2026
Stryker wins FDA clearance for Sonopet 3 ultrasonic bone and tissue removal platform

Stryker has received US Food and Drug Administration (FDA) 510(k) clearance for Sonopet 3, the latest version of its ultrasonic bone and soft tissue removal platform. The company announced the news on October 14, 2026. Stryker developed the platform with input from hundreds of surgeons. It offers more power, precision and versatility, along with two technologies: RISE, which connects the surgical workflow, and Pulse Control, which helps regulate the resection of hard and soft tissues. "They told us they wanted more power, improved ergonomics and enhanced integration," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. The first clinical cases are expected to begin in October. A full commercial launch is planned for later this fall.

Yahoo Finance
Oct 12th, 2026
Stryker shares fall 20% in six months despite 9.2% organic growth and $25.84B revenue

Stryker (NYSE:SYK) shares have fallen 20% over the past six months to $277.82, while the S&P 500 gained 12.8%. The medical device maker develops orthopedic, surgical, neurotechnology, and patient care products that reach over 150 million patients a year. Organic revenue, which excludes acquisitions, divestitures, and currency swings, grew an average of 9.2% year-on-year over the past two years. That suggests Stryker can expand without costly acquisitions. Revenue over the past 12 months was $25.84 billion. Its scale gives it leverage with suppliers in a heavily regulated, competitive market. Free cash flow margin rose 6.5 percentage points over five years to 18.2% for the trailing 12 months. After the drop, the stock trades at 17.4× forward earnings.

Seeking Alpha
Oct 12th, 2026
Stryker to invest $400M in CMR Surgical, with option to buy the robotics maker outright

Stryker announced a $400 million (£300 million) preferred equity investment in CMR Surgical on Monday. The money will support innovation and global expansion of CMR's Versius surgical robotics portfolio. The deal also gives Stryker an exclusive option to acquire 100% of CMR Surgical.